Si Young Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Si Young Choi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- David H. Gracias
Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore MD 21218 USA
3 shared publications - Ruili Zhang
Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore MD 21218 USA
3 shared publications - Wangqu Liu
Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore MD 21218 USA
3 shared publications - Florin M. Selaru
Division of Gastroenterology and Hepatology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
2 shared publications - Ling Li
Division of Gastroenterology and Hepatology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
2 shared publications - Zijian Zhong
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, USA
2 shared publications
Latest Publications
- 24 November 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Sensors Letters
- Vol. 10 (1) , 1-4
InAlN/GaN Detectors for Real-Time Dosimetry in Ultra-High Dose Rate FLASH Radiotherapy
This letter reports the first characterization of InAlN/gallium nitride (GaN)-on-Si solid-state detectors under ultra-high dose-per-pulse (DPP) electron irradiation for FLASH radiotherapy applications. Unpassivated Ni/Au metal-semiconductor-metal and 2-D electron gas (2DEG) interdigitated transducer (IDT) detectors exhibited the best transient performance, with the 2DEG IDT resolving individual pulses as short as 3 μs rise and 325 μs fall times and achieving a signal-to-noise ratio exceeding 220 under 2 Gy pulses. Across a DPP range of 0.05–0.5 Gy, the 2DEG IDT detector demonstrated consistent, dose-dependent voltage responses with sensitivities of 0.5–0.9 V/Gy and a normalized sensitivity of 48.75 nC/Gy/mm$^{2}$, one to two orders of magnitude higher than reported silicon carbide (SiC) and diamond detectors. These results establish InAlN/GaN detectors as promising candidates for compact, high-speed, and radiation-tolerant dosimetry systems capable of real-time single-pulse monitoring in clinical FLASH radiotherapy.
- 24 November 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Sensors Letters
- Vol. 10 (1) , 1-4
InAlN/GaN Detectors for Real-Time Dosimetry in Ultra-High Dose Rate FLASH Radiotherapy
This letter reports the first characterization of InAlN/gallium nitride (GaN)-on-Si solid-state detectors under ultra-high dose-per-pulse (DPP) electron irradiation for FLASH radiotherapy applications. Unpassivated Ni/Au metal-semiconductor-metal and 2-D electron gas (2DEG) interdigitated transducer (IDT) detectors exhibited the best transient performance, with the 2DEG IDT resolving individual pulses as short as 3 μs rise and 325 μs fall times and achieving a signal-to-noise ratio exceeding 220 under 2 Gy pulses. Across a DPP range of 0.05–0.5 Gy, the 2DEG IDT detector demonstrated consistent, dose-dependent voltage responses with sensitivities of 0.5–0.9 V/Gy and a normalized sensitivity of 48.75 nC/Gy/mm$^{2}$, one to two orders of magnitude higher than reported silicon carbide (SiC) and diamond detectors. These results establish InAlN/GaN detectors as promising candidates for compact, high-speed, and radiation-tolerant dosimetry systems capable of real-time single-pulse monitoring in clinical FLASH radiotherapy.
- 5 August 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (29) , e2401407
Untethered Microgrippers for Biopsy in the Upper Urinary Tract
Untethered microrobots offer the possibility to perform medical interventions in anatomically complex and small regions in the body. Presently, it is necessary to access the upper urinary tract to diagnose and treat Upper Tract Urothelial Carcinoma (UTUC). Diagnostic and treatment challenges include ensuring adequate tissue sampling, accurately grading the disease, achieving completeness in endoscopic treatment, and consistently delivering medications to targeted sites. This work introduces microgrippers (µ‐grippers) that are autonomously triggered by physiological temperature for biopsy in the upper urinary tract. The experiments demonstrated that µ‐grippers can be deployed using standard ureteral catheters and maneuvered using an external magnetic field. The μ‐grippers successfully biopsied tissue samples from ex vivo pig ureters, indicating that the thin‐film bilayer springs' autonomous, physiologically triggered actuation exerts enough force to retrieve urinary tract tissue. The quality of these biopsy samples is sufficient for histopathological examination, including hematoxylin and eosin (H&E) and GATA3 immunohistochemical staining. Beyond biopsy applications, the µ‐grippers' small size, wafer‐scale fabrication, and multifunctionality suggest their potential for statistical sampling in the urinary tract. Experimental data and clinical reports underscore this potential through statistical simulations that compare the efficacy of µ‐grippers with conventional tools, such as ureteroscopic forceps and baskets.
- 5 August 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (29) , e2401407
Untethered Microgrippers for Biopsy in the Upper Urinary Tract
Untethered microrobots offer the possibility to perform medical interventions in anatomically complex and small regions in the body. Presently, it is necessary to access the upper urinary tract to diagnose and treat Upper Tract Urothelial Carcinoma (UTUC). Diagnostic and treatment challenges include ensuring adequate tissue sampling, accurately grading the disease, achieving completeness in endoscopic treatment, and consistently delivering medications to targeted sites. This work introduces microgrippers (µ‐grippers) that are autonomously triggered by physiological temperature for biopsy in the upper urinary tract. The experiments demonstrated that µ‐grippers can be deployed using standard ureteral catheters and maneuvered using an external magnetic field. The μ‐grippers successfully biopsied tissue samples from ex vivo pig ureters, indicating that the thin‐film bilayer springs' autonomous, physiologically triggered actuation exerts enough force to retrieve urinary tract tissue. The quality of these biopsy samples is sufficient for histopathological examination, including hematoxylin and eosin (H&E) and GATA3 immunohistochemical staining. Beyond biopsy applications, the µ‐grippers' small size, wafer‐scale fabrication, and multifunctionality suggest their potential for statistical sampling in the urinary tract. Experimental data and clinical reports underscore this potential through statistical simulations that compare the efficacy of µ‐grippers with conventional tools, such as ureteroscopic forceps and baskets.
- 2 December 2023
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 20 (12) , 1801-1822
Untethered shape-changing devices in the gastrointestinal tract
Advances in microfabrication, automation, and computer engineering seek to revolutionize small-scale devices and machines. Emerging trends in medicine point to smart devices that emulate the motility, biosensing abilities, and intelligence of cells and pathogens that inhabit the human body. Two important characteristics of smart medical devices are the capability to be deployed in small conduits, which necessitates being untethered, and the capacity to perform mechanized functions, which requires autonomous shape-changing. We motivate the need for untethered shape-changing devices in the gastrointestinal tract for drug delivery, diagnosis, and targeted treatment. We survey existing structures and devices designed and utilized across length scales from the macro to the sub-millimeter. These devices range from triggerable pre-stressed thin film microgrippers and spring-loaded devices to shape-memory and differentially swelling structures. Recent studies demonstrate that when fully enabled, tether-free and shape-changing devices, especially at sub-mm scales, could significantly advance the diagnosis and treatment of GI diseases ranging from cancer and inflammatory bowel disease (IBD) to irritable bowel syndrome (IBS) by improving treatment efficacy, reducing costs, and increasing medication compliance. We discuss the challenges and possibilities associated with ensuring safe, reliable, and autonomous operation of these smart devices.
- 2 December 2023
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 20 (12) , 1801-1822
Untethered shape-changing devices in the gastrointestinal tract
Advances in microfabrication, automation, and computer engineering seek to revolutionize small-scale devices and machines. Emerging trends in medicine point to smart devices that emulate the motility, biosensing abilities, and intelligence of cells and pathogens that inhabit the human body. Two important characteristics of smart medical devices are the capability to be deployed in small conduits, which necessitates being untethered, and the capacity to perform mechanized functions, which requires autonomous shape-changing. We motivate the need for untethered shape-changing devices in the gastrointestinal tract for drug delivery, diagnosis, and targeted treatment. We survey existing structures and devices designed and utilized across length scales from the macro to the sub-millimeter. These devices range from triggerable pre-stressed thin film microgrippers and spring-loaded devices to shape-memory and differentially swelling structures. Recent studies demonstrate that when fully enabled, tether-free and shape-changing devices, especially at sub-mm scales, could significantly advance the diagnosis and treatment of GI diseases ranging from cancer and inflammatory bowel disease (IBD) to irritable bowel syndrome (IBS) by improving treatment efficacy, reducing costs, and increasing medication compliance. We discuss the challenges and possibilities associated with ensuring safe, reliable, and autonomous operation of these smart devices.
- 6 October 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (10) , 16211-16220
Autonomous Untethered Microinjectors for Gastrointestinal Delivery of Insulin
The delivery of macromolecular drugs via the gastrointestinal (GI) tract is challenging as these drugs display low stability as well as poor absorption across the intestinal epithelium. While permeation-enhancing drug delivery methods can increase the bioavailability of low molecular weight drugs, the effective delivery of high molecular weight drugs across the tight epithelial cell junctions remains a formidable challenge. Here, we describe autonomous microinjectors that are deployed in the GI tract, then efficiently penetrate the GI mucosa to deliver a macromolecular drug, insulin, to the systemic circulation. We performed in vitro studies to characterize insulin release and assess the penetration capability of microinjectors and we measured the in vivo release of insulin in live rats. We found that the microinjectors administered within the luminal GI tract could deliver insulin transmucosally to the systemic circulation at levels similar to those with intravenously administered insulin. Due to their small size, tunability in sizing and dosing, wafer-scale fabrication, and parallel, autonomous operation, we anticipate that these microinjectors will significantly advance drug delivery across the GI tract mucosa to the systemic circulation in a safe manner.
- 6 October 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (10) , 16211-16220
Autonomous Untethered Microinjectors for Gastrointestinal Delivery of Insulin
The delivery of macromolecular drugs via the gastrointestinal (GI) tract is challenging as these drugs display low stability as well as poor absorption across the intestinal epithelium. While permeation-enhancing drug delivery methods can increase the bioavailability of low molecular weight drugs, the effective delivery of high molecular weight drugs across the tight epithelial cell junctions remains a formidable challenge. Here, we describe autonomous microinjectors that are deployed in the GI tract, then efficiently penetrate the GI mucosa to deliver a macromolecular drug, insulin, to the systemic circulation. We performed in vitro studies to characterize insulin release and assess the penetration capability of microinjectors and we measured the in vivo release of insulin in live rats. We found that the microinjectors administered within the luminal GI tract could deliver insulin transmucosally to the systemic circulation at levels similar to those with intravenously administered insulin. Due to their small size, tunability in sizing and dosing, wafer-scale fabrication, and parallel, autonomous operation, we anticipate that these microinjectors will significantly advance drug delivery across the GI tract mucosa to the systemic circulation in a safe manner.